CME Breakfast Symposium · Friday, May 4, 2018 · 7:10 – 8:25am

Management of T2DM Patients with Diabetic Kidney Disease: Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Disease Progression

Target Audience

CMHC West is designed for US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.

Program Overview

Kidney disease has been recognized as a complication of type 2 diabetes mellitus (T2DM) since the 1950s, developing in approximately 35% of patients with T2DM and affecting as many as 50% of patients with diabetes of more than 20 years’ duration. The prevalence of diabetic kidney disease (DKD) in the United States increased from 1988 to 2008 in proportion to the prevalence of diabetes. Among adults with diabetes, the prevalence of DKD has remained stable despite increased use of antihyperglycemic agents and renin-angiotensin-aldosterone system (RAAS) inhibitors.

Newer glucose-lowering agents appear to have glucose-independent effects on diabetic nephropathy and its progression. Recently published analyses of secondary objectives of three key studies, EMPA-REG, CANVAS-R, and LEADER, that assessed cardiovascular outcomes of SGLT2 inhibitors and a GLP-1 receptor agonist (RA) respectively, show positive effects on the development and progression of DKD.

This symposium will provide an overview of the renal effects of antiglycemic agents, particularly GLP-1 RAs and SGLT2 inhibitors. Experts will identify patients who are at the greatest risk for DKD, discuss the underlying physiology of DKD, provide an overview of the mechanisms of action of SGLT2 inhibitors and GLP-1 RAs in relation to renal physiology, and how to effectively manage patients with T2DM and DKD based on the benefits and risks of SGLT2 inhibitors and GLP-1 RAs

Educational Objectives

After completing this activity, the participant should be better able to:

• Describe the relationship between T2DM, hypertension, and cardiorenal syndrome
• Review the most current T2DM algorithms and guidelines for the individualized treatment of complex patients, specifically those with DKD
• Summarize the mode of action and effects of GLP-1 RAs and SGLT-2 inhibitors on renal physiology in patients with T2DM and DKD
• Develop management plans for T2DM patients that consider the recently discovered renal effects of SGLT2 inhibitors and GLP-1 RAs

Faculty

Matthew R. Weir, MD (Chair)

• Professor and Director
• Division of Nephrology
• University of Maryland School of Medicine
• Baltimore, MD

Yehuda Handelsman, MD

• Medical Director and Principal Investigator
• Metabolic Institute of America
• Tarzana, CA

Lance Sloan, MD, FACE, FASN

• Clinical Assistant Professor - UTMB Galveston, TX
• Medical Director of The Texas Institute for Kidney and Endocrine Disorders - Lufkin, TX
• Medical Director of HC Polk Education Center - Lufkin, TX
• Medical Director of SNG Dialysis - Lufkin, TX

Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Cincinnati and CMHC.

The University of Cincinnati is accredited by the ACCME to provide continuing medical education for physicians.

Physician Credit Designation

The University of Cincinnati designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credits commensurate with the extent of their participation in the activity.

Nursing Continuing Education

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

This educational activity for 1.25 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
This activity includes 0.2 pharmacotherapy hours.

Pharmacist Accreditation Statement

Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation

Global Education Group designates this continuing education activity for 1.25 contact hour(s) (0.125 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Numbers (UAN): 0530-9999-18-094-L01-P

Dietician Accreditation Statement

Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR). CDR Credentialed Practitioners will receive 1.25 Continuing Professional Education units (CPEUs) for completion of this activities / materials. CPE Provider #GE012

University of Cincinatti Contact Information

For information about the accreditation of this program, please contact UC at 513-558-7277 or uc-cloudcme@ucmail.uc.edu.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the CMHC Program Evaluation provided at the time of this activity. An evaluation will be available to complete after the symposium via iPads that will be provided to all attendees. Upon completion of the evaluation, participants will be emailed their CME/CE Certificates within 5-7 business days.

Pharmacists Only: In order to receive credit, the ACPE requires that you provide your NABP ePID (6 digits) along with month and date of birth (MMDD) in the online evaluation. After completion of the evaluation via steps outlined above, record of your participation will be uploaded to the CPE Monitor under your NABP e-profile within 60 days. You may print an individual statement of credit for this activity from your NABP e-profile. CMHC strongly encourages you to check your e-profile to ensure your credit is appropriately claimed before July 3, 2018.

Fee Information & Refund/Cancellation Policy

There is registration fee for this educational activity, registration information can be found here.

Disclosure of Conflicts of Interest

The University of Cincinnati requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by the University of Cincinnati for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Cincinnati and CMHC do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Educational Grant Support

This satellite symposium is supported by educational grants from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC. and by Boehringer Ingelheim Pharmaceuticals, Inc. and Lilly USA, LLC.

Joint Providership Statement

This activity is jointly provided by The University of Cincinnati and Tarsus Cardio Inc. dba Cardiometabolic Health Congress for ACCME credit. This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress for ANCC and ACPE credit.

To view the full CMHC West satellite symposia schedule, please visit this page.

To view the full CMHC West agenda, please visit this page